Search

Your search keyword '"De Socio, G. V."' showing total 4 results
Start Over Author "De Socio, G. V." Publisher country:gb
4 results on '"De Socio, G. V."'

1. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?

Author

Bartalucci, C, Baldi, F, Ricci, E, Orofino, G, Menzaghi, B, Ferrara, S, Pellicano', G, Squillace, N, Sarchi, E, Pontali, E, Cenderello, G, Bargiacchi, O, Piccica, M, Carleo, M, Cascio, A, De Socio, G, Bonfanti, P, Di Biagio, A, Bartalucci C., Baldi F., Ricci E., Orofino G., Menzaghi B., Ferrara S., Pellicano' G. F., Squillace N., Sarchi E., Pontali E., Cenderello G., Bargiacchi O., Piccica M., Carleo M. A., Cascio A., De Socio G. V., Bonfanti P., Di Biagio A., Bartalucci, C, Baldi, F, Ricci, E, Orofino, G, Menzaghi, B, Ferrara, S, Pellicano', G, Squillace, N, Sarchi, E, Pontali, E, Cenderello, G, Bargiacchi, O, Piccica, M, Carleo, M, Cascio, A, De Socio, G, Bonfanti, P, Di Biagio, A, Bartalucci C., Baldi F., Ricci E., Orofino G., Menzaghi B., Ferrara S., Pellicano' G. F., Squillace N., Sarchi E., Pontali E., Cenderello G., Bargiacchi O., Piccica M., Carleo M. A., Cascio A., De Socio G. V., Bonfanti P., and Di Biagio A.

Abstract

Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.

Published
2024

2. Weight gain: A possible side effect of all antiretrovirals

Author

Taramasso, L, Ricci, E, Menzaghi, B, Orofino, G, Passerini, S, Madeddu, G, Martinelli, C, De Socio, G, Squillace, N, Rusconi, S, Bonfanti, P, Biagio, A, Quirino, T, Bellacosa, C, Maggi, P, Calza, L, Abeli, C, Celesia, B, Grosso, C, Stagno, A, Vichi, F, Mazzotta, F, Penco, G, Cassola, G, Nicolini, L, Dentone, C, Molteni, C, Palvarini, L, Scalzini, A, Carenzi, L, Rizzardini, G, Valsecchi, L, Cordier, L, Colombo, V, Galli, M, Franzetti, M, Mazzotta, E, Parruti, G, Bagella, P, Mura, M, Libertone, R, Antinori, A, Di Giambenedetto, S, Guastavigna, M, Taramasso L., Ricci E., Menzaghi B., Orofino G., Passerini S., Madeddu G., Martinelli C. V., De Socio G. V., Squillace N., Rusconi S., Bonfanti P., Biagio A. D., Quirino T., Bellacosa C., Maggi P., Calza L., Abeli C., Celesia B. M., Grosso C., Stagno A., Vichi F., Mazzotta F., Penco G., Cassola G., Nicolini L. A., Dentone C., Molteni C., Palvarini L., Scalzini A., Carenzi L., Rizzardini G., Valsecchi L., Cordier L., Colombo V., Galli M., Franzetti M., Mazzotta E., Parruti G., Bagella P., Mura M. S., Libertone R., Antinori A., Di Giambenedetto S., Guastavigna M., Taramasso, L, Ricci, E, Menzaghi, B, Orofino, G, Passerini, S, Madeddu, G, Martinelli, C, De Socio, G, Squillace, N, Rusconi, S, Bonfanti, P, Biagio, A, Quirino, T, Bellacosa, C, Maggi, P, Calza, L, Abeli, C, Celesia, B, Grosso, C, Stagno, A, Vichi, F, Mazzotta, F, Penco, G, Cassola, G, Nicolini, L, Dentone, C, Molteni, C, Palvarini, L, Scalzini, A, Carenzi, L, Rizzardini, G, Valsecchi, L, Cordier, L, Colombo, V, Galli, M, Franzetti, M, Mazzotta, E, Parruti, G, Bagella, P, Mura, M, Libertone, R, Antinori, A, Di Giambenedetto, S, Guastavigna, M, Taramasso L., Ricci E., Menzaghi B., Orofino G., Passerini S., Madeddu G., Martinelli C. V., De Socio G. V., Squillace N., Rusconi S., Bonfanti P., Biagio A. D., Quirino T., Bellacosa C., Maggi P., Calza L., Abeli C., Celesia B. M., Grosso C., Stagno A., Vichi F., Mazzotta F., Penco G., Cassola G., Nicolini L. A., Dentone C., Molteni C., Palvarini L., Scalzini A., Carenzi L., Rizzardini G., Valsecchi L., Cordier L., Colombo V., Galli M., Franzetti M., Mazzotta E., Parruti G., Bagella P., Mura M. S., Libertone R., Antinori A., Di Giambenedetto S., and Guastavigna M.

Abstract

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.

Published
2017

3. Weight gain: A possible side effect of all antiretrovirals

Author

Taramasso, L, Ricci, E, Menzaghi, B, Orofino, G, Passerini, S, Madeddu, G, Martinelli, C, De Socio, G, Squillace, N, Rusconi, S, Bonfanti, P, Biagio, A, Quirino, T, Bellacosa, C, Maggi, P, Calza, L, Abeli, C, Celesia, B, Grosso, C, Stagno, A, Vichi, F, Mazzotta, F, Penco, G, Cassola, G, Nicolini, L, Dentone, C, Molteni, C, Palvarini, L, Scalzini, A, Carenzi, L, Rizzardini, G, Valsecchi, L, Cordier, L, Colombo, V, Galli, M, Franzetti, M, Mazzotta, E, Parruti, G, Bagella, P, Mura, M, Libertone, R, Antinori, A, Di Giambenedetto, S, Guastavigna, M, Taramasso L., Ricci E., Menzaghi B., Orofino G., Passerini S., Madeddu G., Martinelli C. V., De Socio G. V., Squillace N., Rusconi S., Bonfanti P., Biagio A. D., Quirino T., Bellacosa C., Maggi P., Calza L., Abeli C., Celesia B. M., Grosso C., Stagno A., Vichi F., Mazzotta F., Penco G., Cassola G., Nicolini L. A., Dentone C., Molteni C., Palvarini L., Scalzini A., Carenzi L., Rizzardini G., Valsecchi L., Cordier L., Colombo V., Galli M., Franzetti M., Mazzotta E., Parruti G., Bagella P., Mura M. S., Libertone R., Antinori A., Di Giambenedetto S., Guastavigna M., Taramasso, L, Ricci, E, Menzaghi, B, Orofino, G, Passerini, S, Madeddu, G, Martinelli, C, De Socio, G, Squillace, N, Rusconi, S, Bonfanti, P, Biagio, A, Quirino, T, Bellacosa, C, Maggi, P, Calza, L, Abeli, C, Celesia, B, Grosso, C, Stagno, A, Vichi, F, Mazzotta, F, Penco, G, Cassola, G, Nicolini, L, Dentone, C, Molteni, C, Palvarini, L, Scalzini, A, Carenzi, L, Rizzardini, G, Valsecchi, L, Cordier, L, Colombo, V, Galli, M, Franzetti, M, Mazzotta, E, Parruti, G, Bagella, P, Mura, M, Libertone, R, Antinori, A, Di Giambenedetto, S, Guastavigna, M, Taramasso L., Ricci E., Menzaghi B., Orofino G., Passerini S., Madeddu G., Martinelli C. V., De Socio G. V., Squillace N., Rusconi S., Bonfanti P., Biagio A. D., Quirino T., Bellacosa C., Maggi P., Calza L., Abeli C., Celesia B. M., Grosso C., Stagno A., Vichi F., Mazzotta F., Penco G., Cassola G., Nicolini L. A., Dentone C., Molteni C., Palvarini L., Scalzini A., Carenzi L., Rizzardini G., Valsecchi L., Cordier L., Colombo V., Galli M., Franzetti M., Mazzotta E., Parruti G., Bagella P., Mura M. S., Libertone R., Antinori A., Di Giambenedetto S., and Guastavigna M.

Abstract

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.

Published
2017

4. Relations between cardiovascular risk estimates and subclinical atherosclerosis in naïve HIV patients: Results from the HERMES study

Author

De Socio, G, Martinelli, C, Ricci, E, Orofino, G, Valsecchi, L, Vitiello, P, Martinelli, L, Quirino, T, Maggi, P, Bonfanti, P, De Socio G. V. L., Martinelli C., Ricci E., Orofino G., Valsecchi L., Vitiello P., Martinelli L., Quirino T., Maggi P., Bonfanti P., De Socio, G, Martinelli, C, Ricci, E, Orofino, G, Valsecchi, L, Vitiello, P, Martinelli, L, Quirino, T, Maggi, P, Bonfanti, P, De Socio G. V. L., Martinelli C., Ricci E., Orofino G., Valsecchi L., Vitiello P., Martinelli L., Quirino T., Maggi P., and Bonfanti P.

Abstract

The aim of the study was to evaluate the cardiovascular risk factors associated with subclinical carotid atherosclerosis in antiretroviral therapy-naïve HIV-infected patients. The HERMES (HIV Exposure and Risk of Metabolic Syndrome) study enrolled therapy-naïve patients attending hospitals in the Italian coordination group for the study of allergies and HIV infection (CISAI [Coordinamento Italiano per lo Studio Allergia e Infezione da HIV]) in 2007. It was designed to identify metabolic syndrome (MS) and cardiovascular risk factors. The present analysis is a nested cross-sectional study with a subset of patients examined by carotid ultrasonography. Consecutive antiretroviral therapy-naïve HIV patients attending the facilities involved in the CISAI were included. Their 10-year probability of cardiovascular events was calculated using the Framingham Risk Score (FRS) and three other cardiovascular algorithms (the Global Framingham Risk Score - GFRS, 'Progetto Cuore' and 'SCORE'). Vascular age was estimated using a new model derived from GFRS and was compared with chronological age. The diagnosis of MS was based on the National Cholesterol Education Programme and International Diabetes Federation (IDF) definitions. Subclinical atherosclerosis was determined as ultrasound carotid intima-media thickness >0.9 mm. Out of 140 patients enrolled in the HERMES study by the four centres participating in the nested study, a total of 72 (51.4%) subjects, with no overt cardiovascular disease, were examined using carotid ultrasonography. The median age was 40 years, 79.2% men. The vascular age was 7.6 years higher than the chronological age. The factors associated with subclinical atherosclerosis were age (P < 0.0001), vascular age (P = 0.0002), body mass index (P = 0.003), waist circumference (P = 0.0002), MS (IDF definition, P = 0.004) and all the cardiovascular (CV) models (FRS, P = 0.01, GFRS, P = 0.002, Progetto Cuore, P = 0.018, SCORE, P = 0.03). Independent of other

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results